Latest Clinical Trials
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Study of PHN131 in Patients After Surgery PhytoHealth Corporation NA
COMPLETED
(Sep 1, 2026)
PHASE2, PHASE3 Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Alkeus Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections Basilea Pharmaceutica NA
COMPLETED
(Sep 1, 2026)
PHASE3 INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma Inovio Pharmaceuticals NA
COMPLETED
(Sep 1, 2026)
PHASE1, PHASE2 Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine Groupe Francophone des Myelodysplasies NA
COMPLETED
(Sep 1, 2026)
PHASE1, PHASE2 A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus Debiopharm International SA NA
TERMINATED
(Sep 1, 2026)
PHASE2 Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS Zealand Pharma NA
COMPLETED
(Sep 1, 2026)
PHASE3 Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury Merz Pharmaceuticals GmbH NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation Syndax Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Astellas (Beijing) Pharmaceutical R&D Co., Ltd. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee Pacira Pharmaceuticals, Inc NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) Ionis Pharmaceuticals, Inc. NA
COMPLETED
(Sep 1, 2026)
PHASE3 Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Il-Yang Pharm. Co., Ltd. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia Todd C. Lee MD MPH FIDSA NA
RECRUITING
(Sep 1, 2026)
PHASE2 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer Colin D. Weekes, M.D., PhD NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures UCB Biopharma SRL NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Jazz Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) PharmaMar NA
COMPLETED
(Sep 1, 2026)
PHASE3 A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) ReveraGen BioPharma, Inc. NA
COMPLETED
(Sep 1, 2026)
PHASE2 Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus Inventiva Pharma NA
COMPLETED
(Sep 1, 2026)
PHASE2 Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration ORIC Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia Otsuka Pharmaceutical Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia Otsuka Pharmaceutical Co., Ltd. NA
COMPLETED
(Sep 1, 2026)
PHASE3 Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency Ultragenyx Pharmaceutical Inc NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Basilea Pharmaceutica NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy Vertex Pharmaceuticals Incorporated NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer Olema Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Cantex Pharmaceuticals NA
COMPLETED
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML Guangzhou Lupeng Pharmaceutical Company LTD. NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) Vertex Pharmaceuticals Incorporated NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN Lepu Biopharma Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma Debiopharm International SA NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Phase IIIb Study of Ribociclib + ET in Early Breast Cancer Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Benefits of ADHD Treatment in Detained People Stéphanie Baggio NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma Robert Flavell, MD, PhD NA
RECRUITING
(Sep 1, 2026)
PHASE1 Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) Artios Pharma Ltd NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Lurbinectedin in FET-Fused Tumors Children's Hospital of Philadelphia NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD Ultragenyx Pharmaceutical Inc NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations Teva Branded Pharmaceutical Products R&D LLC NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children Philip Spinella NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma Regeneron Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma Regeneron Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas Children's Hospital of Philadelphia NA
RECRUITING
(Sep 1, 2026)
PHASE1 Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) Jerry Lee, MD, MSc, MPhil NA
RECRUITING
(Sep 1, 2026)
PHASE2 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma AskGene Pharma, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias Syndax Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma Guangzhou Lupeng Pharmaceutical Company LTD. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Jazz Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas Caliway Biopharmaceuticals Co., Ltd. NA
COMPLETED
(Sep 1, 2026)
PHASE2 Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study Pharmacotherapies for Alcohol and Substance Use Disorders Alliance NA
RECRUITING
(Sep 1, 2026)
PHASE1 ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia Children's Hospital of Philadelphia NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Pregnenolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study Pharmacotherapies for Alcohol and Substance Use Disorders Alliance NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum LEO Pharma NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment BioMarin Pharmaceutical NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer ToLymph Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE2 CEUS Evaluation of Hydrocephalus in Neonates and Infants Children's Hospital of Philadelphia NA
RECRUITING
(Sep 1, 2026)
PHASE2 BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS BlueSphere Bio, Inc NA
TERMINATED
(Sep 1, 2026)
PHASE1, PHASE2 ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 Milestone Pharmaceuticals Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease Kissei Pharmaceutical Co., Ltd. NA
COMPLETED
(Sep 1, 2026)
PHASE2 A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer UroGen Pharma Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) Swedish Orphan Biovitrum NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML Hemogenyx Pharmaceuticals LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1 Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Vanda Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus Children's Hospital of Philadelphia NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE2 An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Fusion Pharmaceuticals Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia Chong Kun Dang Pharmaceutical NA
RECRUITING
(Sep 1, 2026)
PHASE3 An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria ARS Pharmaceuticals, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs Debiopharm International SA NA
RECRUITING
(Sep 1, 2026)
PHASE3 Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer VSPharmTech Co.,Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE2 DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer Elizabeth Stover, MD, PhD NA
RECRUITING
(Sep 1, 2026)
PHASE1 An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE2 Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA NA
COMPLETED
(Sep 1, 2026)
PHASE2 Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia BioMarin Pharmaceutical NA
ENROLLING BY INVITATION
(Sep 1, 2026)
PHASE3 Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Olema Pharmaceuticals, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Ono Pharmaceutical Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. Guangdong Hengrui Pharmaceutical Co., Ltd NA
COMPLETED
(Sep 1, 2026)
PHASE1 A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat Caliway Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study Testing the Safety and Effects of Single Doses of S1-221 in Healthy Volunteers Delphian Therapeutics Australia Pty, Ltd NA
COMPLETED
(Sep 1, 2026)
PHASE1 Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation Regeneron Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE2 Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) Vertex Pharmaceuticals Incorporated NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome NewAmsterdam Pharma NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Regeneron Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease Sarfez Pharmaceuticals, Inc. NA
WITHDRAWN
(Sep 1, 2026)
PHASE3 A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain AFT Pharmaceuticals, Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects Guangdong Hengrui Pharmaceutical Co., Ltd NA
COMPLETED
(Sep 1, 2026)
PHASE1 Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus Todd C. Lee MD MPH FIDSA NA
TERMINATED
(Sep 1, 2026)
PHASE3 A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants Vertex Pharmaceuticals Incorporated NA
RECRUITING
(Sep 1, 2026)
PHASE1 Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) Sparrow Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE2 A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus LEO Pharma NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis Vanda Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants Vertex Pharmaceuticals Incorporated NA
COMPLETED
(Sep 1, 2026)
PHASE1 Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) Sabine Mueller, MD, PhD NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer Rovi Pharmaceuticals Laboratories NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations Appello Pharmaceuticals, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE2 Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants Vertex Pharmaceuticals Incorporated NA
RECRUITING
(Sep 1, 2026)
PHASE1 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia BioMarin Pharmaceutical NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants Shanghai WD Pharmaceutical Co., Ltd. NA
COMPLETED
(Sep 1, 2026)
PHASE1 Remibrutinib Open Label Roll-over Post-trial Access Protocol Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Jazz Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Evaluate ALN-2232 in Participants With Obesity Alnylam Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. Orphalan NA
RECRUITING
(Sep 1, 2026)
PHASE3 Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE2 Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) Deciphera Pharmaceuticals, LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Guangzhou Lupeng Pharmaceutical Company LTD. NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE1 Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2 Semnur Pharmaceuticals, Inc. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE1 AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer Chugai Pharmaceutical NA
RECRUITING
(Sep 1, 2026)
PHASE1 Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction Qilu Pharmaceutical Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1 Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation Regeneron Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder PleoPharma, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. Novartis Pharmaceuticals NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers CSPC Megalith Biopharmaceutical Co.,Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study Evaluating the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection Hunan Kelun Pharmaceutical Co., Ltd. NA
COMPLETED
(Sep 1, 2026)
PHASE1 A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) ORIC Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML Amphista Therapeutics Ltd NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants Deciphera Pharmaceuticals, LLC NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 Study of Resmetirom in Children and Adolescents With MASH Madrigal Pharmaceuticals, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE2 A 52-week Study of Remibrutinib in IgE-mediated Food Allergy Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer Hamlet Pharma AB NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer CSPC ZhongQi Pharmaceutical Technology Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants Betta Pharmaceuticals Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1 Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants. Betta Pharmaceuticals Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1 A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects Novartis Pharmaceuticals NA
COMPLETED
(Sep 1, 2026)
PHASE1 A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) Novartis Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) Beijing QL Biopharmaceutical Co.,Ltd NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy The Lymphoma Academic Research Organisation NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Guangzhou JOYO Pharma Co., Ltd NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration Qilu Pharmaceutical (Hainan) Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma Ono Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 JH013 Injection in Patients With Primary Sjögren's Syndrome Biotech Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 Safety Study of GMDTC Injection in Participants With Solid Tumors and Cisplatin-Induced Renal Dysfunction Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors Sunshine Lake Pharma Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1 Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan Mario Negri Institute for Pharmacological Research NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult Subjects Hunan Kelun Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause Astellas Pharma Inc NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy BioRay Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Resmetirom in Patients With MASH and HFpEF Madrigal Pharmaceuticals, Inc. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation Shanghai Jeyou Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors CSPC Megalith Biopharmaceutical Co.,Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Phase 3 Randomized Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation Eledon Pharmaceuticals NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders Children's Hospital of Philadelphia NA
COMPLETED
(Aug 1, 2026)
PHASE2 Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis UCB Pharma SA NA
COMPLETED
(Aug 1, 2026)
PHASE3 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis UCB Pharma NA
COMPLETED
(Aug 1, 2026)
PHASE3 A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Aragon Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer Aragon Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Aragon Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC Aragon Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Aragon Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer Aragon Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation Astellas Pharma Inc NA
COMPLETED
(Aug 1, 2026)
PHASE3 A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer Fujifilm Pharmaceuticals U.S.A., Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome Groupe Francophone des Myelodysplasies NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome Groupe Francophone des Myelodysplasies NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease Vertex Pharmaceuticals Incorporated NA
COMPLETED
(Aug 1, 2026)
PHASE2, PHASE3 A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer CStone Pharmaceuticals NA
COMPLETED
(Aug 1, 2026)
PHASE3 Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis Vanda Pharmaceuticals NA
COMPLETED
(Aug 1, 2026)
PHASE3 A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas Novartis Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant Jazz Pharmaceuticals NA
COMPLETED
(Aug 1, 2026)
PHASE2 Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Novartis Pharmaceuticals NA
TERMINATED
(Aug 1, 2026)
PHASE3 A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma Janssen Pharmaceutical K.K. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer Sunshine Lake Pharma Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE3 INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study Stephen J. Kim, MD NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer Janssen Pharmaceutica N.V., Belgium NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy Spectrum Pharmaceuticals, Inc NA
RECRUITING
(Aug 1, 2026)
PHASE2 Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome Taiho Pharmaceutical Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy UCB Biopharma SRL NA
COMPLETED
(Aug 1, 2026)
PHASE3 A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection SymBio Pharmaceuticals NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) Otsuka Pharmaceutical Development & Commercialization, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE3 Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma The Lymphoma Academic Research Organisation NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study Jonathan Schoenfeld, MD, MPH NA
RECRUITING
(Aug 1, 2026)
PHASE2 Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery Averitas Pharma, Inc. NA
COMPLETED
(Aug 1, 2026)
PHASE3 A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 AB122 Platform Study Taiho Pharmaceutical Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1 Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Study of SGN1 in Patients With Advanced Solid Tumor Guangzhou Sinogen Pharmaceutical Co., Ltd NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures UCB Biopharma SRL NA
ENROLLING BY INVITATION
(Aug 1, 2026)
PHASE3 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors Astellas Pharma Global Development, Inc. NA
TERMINATED
(Aug 1, 2026)
PHASE1 Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor Guangzhou Sinogen Pharmaceutical Co., Ltd NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis SATO Pharmaceutical Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Lepu Biopharma Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions Shanghai WD Pharmaceutical Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE1 RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) MedTrace Pharma A/S NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects Rhoshan Pharmaceuticals Inc NA
COMPLETED
(Aug 1, 2026)
PHASE1 Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia Pharmacosmos A/S NA
RECRUITING
(Aug 1, 2026)
PHASE3 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma Novartis Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia Visen Pharmaceuticals (Shanghai) Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE2 Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old Immedica Pharma AB NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations Spectrum Pharmaceuticals, Inc NA
SUSPENDED
(Aug 1, 2026)
PHASE3 A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Surgical Pembro +/- Olaparib w TMZ for rGBM L. Nicolas Gonzalez Castro, MD, PhD NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections Stephanie Wang Zuo NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma Novartis Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer Janssen Pharmaceutical K.K. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas Katy Peters, MD, PhD NA
RECRUITING
(Aug 1, 2026)
PHASE1 Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Karyopharm Therapeutics Inc NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors Beijing Biostar Pharmaceuticals Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes Groupe Francophone des Myelodysplasies NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder Stephen Robert Marder NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia Ascendis Pharma Growth Disorders A/S NA
ENROLLING BY INVITATION
(Aug 1, 2026)
PHASE2, PHASE3 A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma Cho Pharma Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Dose-Escalation Study of Artesunate Patients With IPF Joseph C. Wu NA
RECRUITING
(Aug 1, 2026)
PHASE1 Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections X4 Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma Regeneron Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis Vertex Pharmaceuticals Incorporated NA
COMPLETED
(Aug 1, 2026)
PHASE1 Study of Olutasidenib and Temozolomide in HGG Rigel Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE2 Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells Hideho Okada, MD, PhD NA
RECRUITING
(Aug 1, 2026)
PHASE1 Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ Finn, Olivera, PhD NA
RECRUITING
(Aug 1, 2026)
PHASE1 Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants Jiangsu Aidea Pharmaceutical Group Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation Regeneron Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy UCB Biopharma SRL NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks Octapharma NA
RECRUITING
(Aug 1, 2026)
PHASE3 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation Allist Pharmaceuticals, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE2 Calculating Wall Shear Stress in Infant Pulmonary Veins Children's Hospital of Philadelphia NA
RECRUITING
(Aug 1, 2026)
PHASE1 ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency Inozyme Pharma NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy Lexicon Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer Dongkook Pharmaceutical Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE3 Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV Nicky Mehtani, MD, MPH NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. Vicore Pharma AB NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE Dr. Falk Pharma GmbH NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma Teva Branded Pharmaceutical Products R&D LLC NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) Jiangsu Simcere Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus Arrowhead Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors Novartis Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Avexitide for Treatment of Post-Bariatric Hypoglycemia Amylyx Pharmaceuticals Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases Biostar Pharma, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty Beijing Suncadia Pharmaceuticals Co., Ltd NA
COMPLETED
(Aug 1, 2026)
PHASE3 A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. Novartis Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines Novartis Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee Pacira Pharmaceuticals, Inc NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. Paradigm Biopharmaceuticals Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients Intergroupe Francophone du Myelome NA
RECRUITING
(Aug 1, 2026)
PHASE3 Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation Allist Pharmaceuticals, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases Allist Pharmaceuticals, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Lepu Biopharma Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE2 A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis LEO Pharma NA
RECRUITING
(Aug 1, 2026)
PHASE2 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation Apellis Pharmaceuticals, Inc. NA
WITHDRAWN
(Aug 1, 2026)
PHASE3 A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1 Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Cinclus Pharma Holding AB NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type Wanbangde Pharmaceutical Group Co., LTD NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) Dizal Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism Ascendis Pharma Bone Diseases A/S NA
RECRUITING
(Aug 1, 2026)
PHASE3 Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma Telix Pharmaceuticals (Innovations) Pty Limited NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer Jazz Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE2 ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy Jiangsu Aosaikang Pharmaceutical Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma Stephanie Berg NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. Xerient Pharma NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation Syndax Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections Octapharma NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures Jazz Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors Astellas Pharma Global Development, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 VEL-101 to Prevent Rejection After Kidney Transplantation Veloxis Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE2 Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide Beijing Continent Pharmaceutical Co, Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE1 Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease Regeneron Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH Madrigal Pharmaceuticals, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE2 ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Newave Pharmaceutical Inc NA
RECRUITING
(Aug 1, 2026)
PHASE3 Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Sabine Mueller, MD, PhD NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE3 A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2 Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease Intergroupe Francophone de Cancerologie Thoracique NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together Otsuka Pharmaceutical Development & Commercialization, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Study of CS060380 Tablets in Patients With MASH and Obesity Cascade Pharmaceuticals, Inc NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers Regeneron Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD Regeneron Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc NA
RECRUITING
(Aug 1, 2026)
PHASE3 Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus Mapi Pharma Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants Vertex Pharmaceuticals Incorporated NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH Jazz Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) Verrica Pharmaceuticals Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE3 Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations Jacobio Pharmaceuticals Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2 Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Vanda Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia AFT Pharmaceuticals, Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) Novartis Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer CSPC Megalith Biopharmaceutical Co.,Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2 Evaluate the Efficacy and Safety of CTO0307 in Adults With Presbyopia Taejoon Pharmaceutical Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE3 VG081821AC Tablets for Early to Mid-stage Parkinson's Disease Zhejiang Vimgreen Pharmaceuticals, Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC Jiangsu Hansoh Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Psilocybin Therapy for Methamphetamine Use Disorder and HIV Nicky Mehtani, MD, MPH NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Bridging Study of XKH001 in Healthy Adult Caucasian Participants Zhejiang Kanova Biopharmaceutical Co., LTD NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC CSPC Megalith Biopharmaceutical Co.,Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2 ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Jiangsu Aosaikang Pharmaceutical Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) Shandong New Time Pharmaceutical Co., LTD NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504 Jiangsu Hansoh Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Evaluation of PAN-90806 Eye Drops in Healthy Subjects Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma Corbus Pharmaceuticals Inc. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma Lunan Better Pharmaceutical Co., LTD. NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504 Jiangsu Hansoh Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B Sunshine Lake Pharma Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1 ONE-P TMS First Responders Fidel Vila-Rodriguez, MD, PhD, FRCPC, DFAPA NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis Guangzhou Lupeng Pharmaceutical Company LTD. NA
RECRUITING
(Aug 1, 2026)
PHASE2 ONE-P TMS Military Veterans Fidel Vila-Rodriguez, MD, PhD, FRCPC, DFAPA NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer Astellas Pharma Global Development, Inc. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer Chengdu JOYO pharma Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). Beijing InnoCare Pharma Tech Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Study of NXP900 With Lorlatinib in ALK+ Lung Cancer Nuvectis Pharma, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1 Genistein for the Reduction of Adverse Cardiovascular Events (GRACE) London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer Haisco Pharmaceutical Group Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study of Ferric Derisomaltose Injection in Chinese Participants With Iron Deficiency Anemia Under Fasting Conditions Sichuan Huiyu Pharmaceutical Co., Ltd NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Taizhou Mabtech Pharmaceutical Co.,Ltd NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 26DT052; Scaling Busulfan Dose to Body Surface Area in Children Children's Hospital of Philadelphia NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea. Sun Pharmaceutical Industries, Inc. NA
COMPLETED
(Aug 1, 2026)
PHASE1 Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects Jiangsu vcare pharmaceutical technology co., LTD NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin CSPC Ouyi Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer Jiangsu Alphamab Biopharmaceuticals Co., Ltd NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer Qilu Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma Shanghai Xin Huanghe Pharmaceutical Co., Ltd. NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers Advenchen Pharmaceuticals, LLC. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers Advenchen Pharmaceuticals, LLC. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks Novartis Pharmaceuticals NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 "SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Jul 1, 2026)
PHASE3 A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Jul 1, 2026)
PHASE3 Study of Ascending Levels of Tolvaptan in Hyponatremia Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Jul 1, 2026)
PHASE3 Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD) Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Jul 1, 2026)
PHASE3 Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) Novartis Pharmaceuticals NA
COMPLETED
(Jul 1, 2026)
PHASE2 Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients Novartis Pharmaceuticals NA
COMPLETED
(Jul 1, 2026)
PHASE2 Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Acerta Pharma BV NA
COMPLETED
(Jul 1, 2026)
PHASE2 Selinexor and Backbone Treatments of Multiple Myeloma Patients Karyopharm Therapeutics Inc NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy The Lymphoma Academic Research Organisation NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC Joseph J. Cullen, MD, FACS NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia Novartis Pharmaceuticals NA
COMPLETED
(Jul 1, 2026)
PHASE2 A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Adam Burgoyne, MD, PhD NA
COMPLETED
(Jul 1, 2026)
PHASE2 A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Novartis Pharmaceuticals NA
TERMINATED
(Jul 1, 2026)
PHASE2 Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism Zealand Pharma NA
COMPLETED
(Jul 1, 2026)
PHASE3 Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome X4 Pharmaceuticals NA
COMPLETED
(Jul 1, 2026)
PHASE3 A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS Mapi Pharma Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 ENCOrafenib With Binimetinib in bRAF NSCLC Intergroupe Francophone de Cancerologie Thoracique NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) Vanda Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures UCB Biopharma SRL NA
RECRUITING
(Jul 1, 2026)
PHASE3 Acetazolamide for Treatment Resistant Schizophrenia Vishwajit Nimgaonkar, MD PhD NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee Steven E Harte, PhD NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Jul 1, 2026)
PHASE2 RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee Overseas Pharmaceuticals, Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study of ASP3082 in Adults With Advanced Solid Tumors Astellas Pharma Inc NA
RECRUITING
(Jul 1, 2026)
PHASE1 Study of ORIC-944 in Patients With Metastatic Prostate Cancer ORIC Pharmaceuticals NA
RECRUITING
(Jul 1, 2026)
PHASE1 Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) Phanes Therapeutics NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty Foresee Pharmaceuticals Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) Madrigal Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC Wuhan YZY Biopharma Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study of ASP1002 in Adults for Treatment of Solid Tumors Astellas Pharma Global Development, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE1 Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients International Extranodal Lymphoma Study Group (IELSG) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) Milestone Pharmaceuticals Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE2 Tolerability of MDMA in Schizophrenia Anya Bershad, MD, PhD NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) OrphAI Therapeutics NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer Regeneron Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Kisspeptin Administration Subcutaneously to Patients With IHH Stephanie B. Seminara, MD NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder. Luye Pharma Group Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation Eledon Pharmaceuticals NA
COMPLETED
(Jul 1, 2026)
PHASE2 Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) Jerry Vockley, MD, PhD NA
SUSPENDED
(Jul 1, 2026)
PHASE2 Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old Teva Branded Pharmaceutical Products R&D, Inc. NA
COMPLETED
(Jul 1, 2026)
PHASE1 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms R-Pharm NA
COMPLETED
(Jul 1, 2026)
PHASE1 Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women Rovi Pharmaceuticals Laboratories NA
COMPLETED
(Jul 1, 2026)
PHASE1 A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Ascentage Pharma Group Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE3 Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma R-Pharm NA
COMPLETED
(Jul 1, 2026)
PHASE3 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Shenzhen HighTide Biopharmaceutical Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults Pharmosa Biopharm Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE1 A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) Children's Hospital of Philadelphia NA
RECRUITING
(Jul 1, 2026)
PHASE2 The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) Telix Pharmaceuticals (Innovations) Pty Limited NA
RECRUITING
(Jul 1, 2026)
PHASE3 Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension Quivive Pharma, Inc. NA
COMPLETED
(Jul 1, 2026)
PHASE1 Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia Novartis Pharmaceuticals NA
RECRUITING
(Jul 1, 2026)
PHASE3 Impact of Daily Oral Cannabis Doses in Patients With Cancer Shanna Babalonis, PhD NA
RECRUITING
(Jul 1, 2026)
PHASE1 D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer InnoPharmax Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE3 A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes Fujian Shengdi Pharmaceutical Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 Aging Resilience Through Microbiota Optimization and Regulation Gonzalo Jorquera, PhD NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults (18-55 Years) Basilea Pharmaceutica NA
COMPLETED
(Jul 1, 2026)
PHASE1 Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination Basilea Pharmaceutica NA
RECRUITING
(Jul 1, 2026)
PHASE1 Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants Gan and Lee Pharmaceuticals, USA NA
COMPLETED
(Jul 1, 2026)
PHASE2 A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis Novartis Pharmaceuticals NA
RECRUITING
(Jul 1, 2026)
PHASE3 CRF2 Agonist for the Treatment of Worsening Heart Failure Corteria Pharmaceuticals NA
SUSPENDED
(Jul 1, 2026)
PHASE2 A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function X4 Pharmaceuticals NA
COMPLETED
(Jul 1, 2026)
PHASE1 Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus Arrowhead Pharmaceuticals NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE3 Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery EyeD Pharma NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy Myopharm Limited NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS PhenoNet, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy Lyell Immunopharma, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE3 A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis Novartis Pharmaceuticals NA
RECRUITING
(Jul 1, 2026)
PHASE3 Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma Alpheus Medical, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE2 Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone Sparrow Pharmaceuticals NA
COMPLETED
(Jul 1, 2026)
PHASE1 Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy Vertex Pharmaceuticals Incorporated NA
RECRUITING
(Jul 1, 2026)
PHASE3 Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma Glonova Pharma Co., Ltd NA
RECRUITING
(Jul 1, 2026)
PHASE1 A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA Cascade Pharmaceuticals, Inc NA
RECRUITING
(Jul 1, 2026)
PHASE3 Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Novartis Pharmaceuticals NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer R-Pharm NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease Stephen G. Kaler NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma R-Pharm NA
COMPLETED
(Jul 1, 2026)
PHASE1 A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma R-Pharm NA
COMPLETED
(Jul 1, 2026)
PHASE3 CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Stephan Grupp MD PhD NA
RECRUITING
(Jul 1, 2026)
PHASE1 Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. LB Pharmaceuticals Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE3 A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE3 A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body Otsuka Pharmaceutical Development & Commercialization, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE1 A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers Daewoong Pharmaceutical Co. LTD. NA
RECRUITING
(Jul 1, 2026)
PHASE1 A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations R-Pharm NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE3 CBP-0276 to Reduce Opioid Use in Adults Undergoing Major Orthopedic Surgery Clarent Biopharma, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE2 Neonatal White Matter Injury Trial (WRAP) Bridget LaMonica Ostrem, M.D., Ph.D. NA
RECRUITING
(Jul 1, 2026)
PHASE1 Pharmacokinetic Effect of Y-3 for Injection on Rosuvastatin Calcium Tablets in Healthy Participants Neurodawn Pharmaceutical Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE1 Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients Qanatpharma AG NA
RECRUITING
(Jul 1, 2026)
PHASE2 Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet Reistone Biopharma Company Limited NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery Shanghai Huilun Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism Ascendis Pharma A/S NA
RECRUITING
(Jul 1, 2026)
PHASE3 A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery Shanghai Huilun Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting Fujian Shengdi Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2 Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Taiho Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE3 Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Dizal Pharmaceuticals NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis. Newsoara Biopharma Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 HPP737 in Adult Patients With Plaque Psoriasis Newsoara Biopharma Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis Shanghai Ark Biopharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Y-6 Sublingual Tablets for Acute Penetrating Artery Infarction Neurodawn Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Phase II Study of QLC2519 in Pediatric Solid Tumor Participants Qilu Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE2 Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain Staci Gruber, Ph.D. NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer Daewoong Pharmaceutical Co. LTD. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years. Nanjing Zenshine Pharmaceuticals NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer Lumos Pharma NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1) Caliway Biopharmaceuticals Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer Lepu Biopharma Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) Eddingpharm (Zhuhai) Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations The Lymphoma Academic Research Organisation NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel Disease Jiangsu Aosaikang Pharmaceutical Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) The Lymphoma Academic Research Organisation NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 ASKC200 for Knee Osteoarthritis Pain Jiangsu Aosaikang Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer CSPC Megalith Biopharmaceutical Co.,Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions Jiangsu Aidea Pharmaceutical Group Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE1 Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults Lumos Pharma NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. BioCryst Pharmaceuticals NA
WITHDRAWN
(Jun 1, 2026)
PHASE3 Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® Astellas Pharma Europe Ltd. NA
COMPLETED
(Jun 1, 2026)
PHASE2 SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss Sound Pharmaceuticals, Incorporated NA
WITHDRAWN
(Jun 1, 2026)
PHASE2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Karyopharm Therapeutics Inc NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy Astellas Pharma Global Development, Inc. NA
COMPLETED
(Jun 1, 2026)
PHASE3 SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity Sound Pharmaceuticals, Incorporated NA
COMPLETED
(Jun 1, 2026)
PHASE2 Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Deciphera Pharmaceuticals, LLC NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria Children's Hospital of Philadelphia NA
RECRUITING
(Jun 1, 2026)
PHASE2 PG2 Breast Cancer Evaluation in Adjuvant Medicine Study PhytoHealth Corporation NA
COMPLETED
(Jun 1, 2026)
PHASE2 Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant Novartis Pharmaceuticals NA
TERMINATED
(Jun 1, 2026)
PHASE3 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma Novartis Pharmaceuticals NA
COMPLETED
(Jun 1, 2026)
PHASE3 Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs. Stephan Busque NA
RECRUITING
(Jun 1, 2026)
PHASE1 Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects Novartis Pharmaceuticals NA
TERMINATED
(Jun 1, 2026)
PHASE3 Study Evaluating Subjects With Distal Renal Tubular Acidosis Advicenne Pharma NA
TERMINATED
(Jun 1, 2026)
PHASE3 Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. Novartis Pharmaceuticals NA
COMPLETED
(Jun 1, 2026)
PHASE2 Troriluzole in Adult Participants With Spinocerebellar Ataxia Biohaven Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia Ascendis Pharma A/S NA
COMPLETED
(Jun 1, 2026)
PHASE2 Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Sabine Mueller, MD, PhD NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Scott R. Plotkin, MD, PhD NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Karyopharm Therapeutics Inc NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease Keryx Biopharmaceuticals NA
SUSPENDED
(Jun 1, 2026)
PHASE3 A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Study to Evaluate the Safety and Tolerability of EP0042 Ellipses Pharma NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC Intercept Pharmaceuticals NA
TERMINATED
(Jun 1, 2026)
PHASE2 The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection PharmaEssentia NA
COMPLETED
(Jun 1, 2026)
PHASE1 Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected Novartis Pharmaceuticals NA
TERMINATED
(Jun 1, 2026)
PHASE3 A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Mirum Pharmaceuticals, Inc. NA
COMPLETED
(Jun 1, 2026)
PHASE2 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD Apellis Pharmaceuticals, Inc. NA
COMPLETED
(Jun 1, 2026)
PHASE3 A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease Ultragenyx Pharmaceutical Inc NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older The Lymphoma Academic Research Organisation NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP) Grant Dorsey, M.D, Ph.D. NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments Regeneron Pharmaceuticals NA
RECRUITING
(Jun 1, 2026)
PHASE1 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC Intercept Pharmaceuticals NA
COMPLETED
(Jun 1, 2026)
PHASE2 LYL273 for Patients With Relapsed or Refractory mCRC Lyell Immunopharma, Inc. NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) Vertex Pharmaceuticals Incorporated NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) Vertex Pharmaceuticals Incorporated NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma ARS Pharmaceuticals, Inc. NA
COMPLETED
(Jun 1, 2026)
PHASE2 A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH Alexion Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. Sun Pharmaceutical Industries Limited NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies Ellipses Pharma NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia Ascendis Pharma Growth Disorders A/S NA
COMPLETED
(Jun 1, 2026)
PHASE2, PHASE3 Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate Sumitomo Pharma America, Inc. NA
COMPLETED
(Jun 1, 2026)
PHASE3 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery Regeneron Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia Ocuphire Pharma, Inc. NA
COMPLETED
(Jun 1, 2026)
PHASE3 Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) Novartis Pharmaceuticals NA
COMPLETED
(Jun 1, 2026)
PHASE3 A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection Respirion Pharmaceuticals Pty Ltd NA
COMPLETED
(Jun 1, 2026)
PHASE1, PHASE2 Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) PharmaMar NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 The Lymphoma Academic Research Organisation NA
RECRUITING
(Jun 1, 2026)
PHASE3 A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis Avalyn Pharma Inc. NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure Jens D Hove, MD,PHD NA
RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older Vertex Pharmaceuticals Incorporated NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer Beijing Wehand-Bio Pharmaceutical Co., Ltd NA
COMPLETED
(Jun 1, 2026)
PHASE2 Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder Knoa Pharma LLC NA
COMPLETED
(Jun 1, 2026)
PHASE2 Study of Sunobinop on Craving in Alcohol Use Disorder Knoa Pharma LLC NA
COMPLETED
(Jun 1, 2026)
PHASE2 Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer Ono Pharmaceutical Co., Ltd. NA
COMPLETED
(Jun 1, 2026)
PHASE1 Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects Shanghai Ark Biopharmaceutical Co., Ltd. NA
COMPLETED
(Jun 1, 2026)
PHASE1 Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy Vertex Pharmaceuticals Incorporated NA
RECRUITING
(Jun 1, 2026)
PHASE3 Phase 2 Study of Rapcabtagene Autoleucel in Myositis Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Suvorexant for Treatment of AUD and PTSD Pharmacotherapies for Alcohol and Substance Use Disorders Alliance NA
RECRUITING
(Jun 1, 2026)
PHASE2 Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID) Napo Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) Jerry Vockley, MD, PhD NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial Step Pharma, SAS NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Study of PHST001 in Advanced Solid Tumors Pheast Therapeutics NA
RECRUITING
(Jun 1, 2026)
PHASE1 Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab The Lymphoma Academic Research Organisation NA
RECRUITING
(Jun 1, 2026)
PHASE2 Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Vanda Pharmaceuticals NA
RECRUITING
(Jun 1, 2026)
PHASE3 Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma Qilu Pharmaceutical Co., Ltd. NA
RECRUITING
(Jun 1, 2026)
PHASE2 Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) Jerry Vockley, MD, PhD NA
WITHDRAWN
(Jun 1, 2026)
PHASE2 An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA) Jerry Vockley, MD, PhD NA
ENROLLING BY INVITATION
(Jun 1, 2026)
PHASE1 A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) Dizal Pharmaceuticals NA
RECRUITING
(Jun 1, 2026)
PHASE2 18F-mFBG Cardiac Uptake With Lewy Body Dementia Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) NA
RECRUITING
(Jun 1, 2026)
PHASE2 TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Novartis Pharmaceuticals NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer Qilu Pharmaceutical Co., Ltd. NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio Apellis Pharmaceuticals, Inc. NA
RECRUITING
(Jun 1, 2026)
PHASE2 Transition to KPL-387 Monotherapy Dosing & Administration Study Kiniksa Pharmaceuticals International, plc NA
RECRUITING
(Jun 1, 2026)
PHASE2 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Nacuity Pharmaceuticals, Inc. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects Rhoshan Pharmaceuticals Inc NA
COMPLETED
(Jun 1, 2026)
PHASE1 A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Regeneron Pharmaceuticals NA
WITHDRAWN
(Jun 1, 2026)
PHASE2, PHASE3 Drug Interaction and Food Effect Study of CS0159 Cascade Pharmaceuticals, Inc NA
COMPLETED
(Jun 1, 2026)
PHASE1 Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization Fondation Hôpital Saint-Joseph NA
RECRUITING
(Jun 1, 2026)
PHASE3 A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Jun 1, 2026)
PHASE3 Sitagliptin in Recurrent/Progressive Grade 4 Glioma Kailin Yang, MD, PhD NA
RECRUITING
(Jun 1, 2026)
PHASE1 A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Jun 1, 2026)
PHASE1 Pharmacokinetic (PK) Evaluation of Nalmefene Formulations Knoa Pharma LLC NA
COMPLETED
(Jun 1, 2026)
PHASE1 A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Novartis Pharmaceuticals NA
WITHDRAWN
(Jun 1, 2026)
PHASE1, PHASE2 Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Telomir Pharmaceuticals, Inc. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma Christopher Strouse NA
RECRUITING
(Jun 1, 2026)
PHASE1 Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat Caliway Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Jun 1, 2026)
PHASE2 Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. Federation Francophone de Cancerologie Digestive NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 QLC5508 in Participants With Metastatic Prostate Cancer Qilu Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Kalinski, Pawel, MD, PhD NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension SpyGlass Pharma, Inc. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1 A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion Shanghai Jeyou Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1 A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) Changchun GeneScience Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1 A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer Beijing Biostar Pharmaceuticals Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer Jiangsu Hansoh Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1 Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zhifeng Zhao, PhD NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder Chengdu Kanghong Pharmaceutical Group Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(May 1, 2026)
PHASE1 Intramuscular Peramivir for the Treatment of Uncomplicated Influenza BioCryst Pharmaceuticals NA
WITHDRAWN
(May 1, 2026)
PHASE3 Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(May 1, 2026)
PHASE3 ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Addressing Involuntary Movements in Tardive Dyskinesia Auspex Pharmaceuticals, Inc. NA
COMPLETED
(May 1, 2026)
PHASE3 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions Hunan Kelun Pharmaceutical Co., Ltd. NA
COMPLETED
(May 1, 2026)
PHASE1 Bioequivalence Study of Gefitinib Tablets Under Fed Conditions Hunan Kelun Pharmaceutical Co., Ltd. NA
COMPLETED
(May 1, 2026)
PHASE1 Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Regeneron Pharmaceuticals NA
COMPLETED
(May 1, 2026)
PHASE3 Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
TERMINATED
(May 1, 2026)
PHASE3 INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) Inovio Pharmaceuticals NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative Sunshine Lake Pharma Co., Ltd. NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS Zynerba Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Medication Treatment for Opioid Use Disorder in Expectant Mothers T. John Winhusen, PhD NA
COMPLETED
(May 1, 2026)
PHASE3 MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients St. Joseph's Hospital and Medical Center, Phoenix NA
COMPLETED
(May 1, 2026)
PHASE2 A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer Changchun GeneScience Pharmaceutical Co., Ltd. NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Regeneron Pharmaceuticals NA
COMPLETED
(May 1, 2026)
PHASE2, PHASE3 Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans Pharmacotherapies for Alcohol and Substance Use Disorders Alliance NA
COMPLETED
(May 1, 2026)
PHASE2 Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy Sumitomo Pharma Switzerland GmbH NA
COMPLETED
(May 1, 2026)
PHASE3 A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm Merz Pharmaceuticals GmbH NA
COMPLETED
(May 1, 2026)
PHASE2 Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
COMPLETED
(May 1, 2026)
PHASE3 A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer Regeneron Pharmaceuticals NA
TERMINATED
(May 1, 2026)
PHASE2 Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) Madrigal Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia Milestone Pharmaceuticals Inc. NA
COMPLETED
(May 1, 2026)
PHASE3 Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification Hutchison Medipharma Limited NA
COMPLETED
(May 1, 2026)
PHASE3 TriPRIL CAR T Cells in Multiple Myeloma Marcela V. Maus, M.D.,Ph.D. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 PM14 Administered Intravenously to Patients With Advanced Solid Tumors PharmaMar NA
COMPLETED
(May 1, 2026)
PHASE1 Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan Novartis Pharmaceuticals NA
COMPLETED
(May 1, 2026)
PHASE2 A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML Sunshine Lake Pharma Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors Hutchison Medipharma Limited NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 A Study of KL590586 in Patients With Advanced Solid Tumors Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Effect of Ensifentrine on Sputum Markers of Inflammation in COPD Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA NA
RECRUITING
(May 1, 2026)
PHASE2 KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer CStone Pharmaceuticals NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy Biohaven Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE2 A Study of SKB315 in Patients With Advanced Solid Tumors Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE1 Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer Jiangsu Alphamab Biopharmaceuticals Co., Ltd NA
COMPLETED
(May 1, 2026)
PHASE2 Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age Vertex Pharmaceuticals Incorporated NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) Phanes Therapeutics NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts Novartis Pharmaceuticals NA
COMPLETED
(May 1, 2026)
PHASE2 PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial KalVista Pharmaceuticals, Ltd. NA
COMPLETED
(May 1, 2026)
PHASE3 DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Day One Biopharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) Dizal Pharmaceuticals NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma CStone Pharmaceuticals NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition Joseph Oved NA
RECRUITING
(May 1, 2026)
PHASE2 A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b Shanghai Vitalgen BioPharma Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE1 A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Regeneron Pharmaceuticals NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer Wuhan YZY Biopharma Co., Ltd. NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 ZILRETTA in Subjects With Shoulder Osteoarthritis Pacira Pharmaceuticals, Inc NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) Lyvgen Biopharma Holdings Limited NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature BioMarin Pharmaceutical NA
RECRUITING
(May 1, 2026)
PHASE2 In-office Repair of Chronic Tympanic Membrane Perforations D. Bradley Welling, MD, PhD NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors Shanghai Hengrui Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate Intercept Pharmaceuticals NA
TERMINATED
(May 1, 2026)
PHASE3 Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia Novartis Pharmaceuticals NA
RECRUITING
(May 1, 2026)
PHASE3 SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Shanghai Hengrui Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder T. John Winhusen, PhD NA
RECRUITING
(May 1, 2026)
PHASE2 Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer Intergroupe Francophone de Cancerologie Thoracique NA
RECRUITING
(May 1, 2026)
PHASE2 A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China Santen Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Intralesional Injection of STS in Treatment of Calcinosis Robyn T. Domsic, MD, MPH NA
RECRUITING
(May 1, 2026)
PHASE2 The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia. Sichuan Kelun Pharmaceutical Co., Ltd NA
RECRUITING
(May 1, 2026)
PHASE1 A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease Ribocure Pharmaceuticals AB NA
COMPLETED
(May 1, 2026)
PHASE2 Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months Fondation Ophtalmologique Adolphe de Rothschild NA
RECRUITING
(May 1, 2026)
PHASE2 Opioid Drug Interaction Study Shanna Babalonis, PhD NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options Mundipharma Research Limited NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures Supernus Pharmaceuticals, Inc. NA
RECRUITING
(May 1, 2026)
PHASE2 A Study of SKB518 in Patients With Lung Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE2 TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution Unither Pharmaceuticals, France NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) Dizal Pharmaceuticals NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention Children's Hospital of Philadelphia NA
RECRUITING
(May 1, 2026)
PHASE1 A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia European Group for Research In Schizophrenia NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis Otsuka Pharmaceutical Development & Commercialization, Inc. NA
RECRUITING
(May 1, 2026)
PHASE3 A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer J-Pharma Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol BioCorRx Pharmaceuticals Inc NA
RECRUITING
(May 1, 2026)
PHASE1 A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions Shanghai Shengdi Pharmaceutical Co., Ltd NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Y-4 to Treat the Postherpetic Neuralgia Neurodawn Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE2 SKB500 Combinations in Patients With Small Cell Lung Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE2 A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Cinclus Pharma Holding AB NA
WITHDRAWN
(May 1, 2026)
PHASE3 Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer Daewoong Pharmaceutical Co. LTD. NA
RECRUITING
(May 1, 2026)
PHASE1 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC CSPC Megalith Biopharmaceutical Co.,Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin Hanmi Pharmaceutical Company Limited NA
RECRUITING
(May 1, 2026)
PHASE3 Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 Androgen-responsive POSLUMA-guided Intra-prostatic Boost Martin T. King, MD, PhD NA
RECRUITING
(May 1, 2026)
PHASE2 A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE2 Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole Acesion Pharma NA
COMPLETED
(May 1, 2026)
PHASE1 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy Volunteers Hunan Kelun Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE1 Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery. CSPC Ouyi Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE1 Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol Celltrion Pharm, Inc. NA
COMPLETED
(May 1, 2026)
PHASE3 A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Novelwise Pharmaceutical Corporation NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens Shenzhen Salubris Pharmaceuticals Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE2 A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors Health Hope Pharma NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 A Phase 1, First-in-human Study of VX-433 Vertex Pharmaceuticals Incorporated NA
RECRUITING
(May 1, 2026)
PHASE1 A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds Ono Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. Taizhou Mabtech Pharmaceutical Co.,Ltd NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia. Andros Pharmaceuticals Co., Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2, PHASE3 A Study to Evaluate the Efficacy and Safety of UI022/UI023 Korea United Pharm. Inc. NA
COMPLETED
(May 1, 2026)
PHASE3 A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia Kissei Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE2 Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants Under Fasting Conditions Sichuan Huiyu Pharmaceutical Co., Ltd NA
RECRUITING
(May 1, 2026)
PHASE1 The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori Xuanzhu Biopharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas Shanghai Runshi Pharmaceutical Technology Co., Ltd NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants Neurodawn Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 A Study of IMM0306 in IgG4-Related Disease ImmuneOnco Biopharmaceuticals (Shanghai) Inc. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2, PHASE3 A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid CSPC Ouyi Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease R-Pharm International, LLC NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） CSPC Megalith Biopharmaceutical Co.,Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ Qilu Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD). Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE3 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE3 IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE2 Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment International Extranodal Lymphoma Study Group (IELSG) NA
COMPLETED
(Apr 1, 2026)
PHASE2 Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design Christopher Wilke NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1 A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies Constellation Pharmaceuticals NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1 A Phase 1 Study Comparing AVP-786 With AVP-923 Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acerta Pharma BV NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1 Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS Mapi Pharma Ltd. NA
TERMINATED
(Apr 1, 2026)
PHASE2 A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide Sarfez Pharmaceuticals, Inc. NA
TERMINATED
(Apr 1, 2026)
PHASE1 Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] Karyopharm Therapeutics Inc NA
COMPLETED
(Apr 1, 2026)
PHASE3 Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL The Lymphoma Academic Research Organisation NA
COMPLETED
(Apr 1, 2026)
PHASE3 MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas International Extranodal Lymphoma Study Group (IELSG) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study Angus W. Thomson PhD DSc NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects AMAG Pharmaceuticals, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE3 Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease Insud Pharma NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer Phoenix Molecular Designs NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Mundipharma Research Limited NA
COMPLETED
(Apr 1, 2026)
PHASE3 A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc NA
RECRUITING
(Apr 1, 2026)
PHASE1 Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Karyopharm Therapeutics Inc NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Interdialytic Peritoneal UltraFiltration in HemoDialysis Patients London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder Biohaven Pharmaceuticals, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE3 Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent Novartis Pharmaceuticals NA
TERMINATED
(Apr 1, 2026)
PHASE2 A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme CNS Pharmaceuticals, Inc. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE2 Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors Deciphera Pharmaceuticals, LLC NA
TERMINATED
(Apr 1, 2026)
PHASE1 A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
TERMINATED
(Apr 1, 2026)
PHASE2 Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx Hansa Biopharma AB NA
COMPLETED
(Apr 1, 2026)
PHASE3 Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Novartis Pharmaceuticals NA
COMPLETED
(Apr 1, 2026)
PHASE3 Phase ll Study of HEC585 in Patients With IPF Sunshine Lake Pharma Co., Ltd. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. Novartis Pharmaceuticals NA
COMPLETED
(Apr 1, 2026)
PHASE1 A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension Janssen Pharmaceutical K.K. NA
COMPLETED
(Apr 1, 2026)
PHASE3 A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Psilocybin Therapy for Chronic Low Back Pain Joshua Woolley, MD, PhD NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema LEO Pharma NA
COMPLETED
(Apr 1, 2026)
PHASE3 Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts Hansa Biopharma AB NA
COMPLETED
(Apr 1, 2026)
PHASE3 TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE3 A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies Faron Pharmaceuticals Ltd NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma Lantern Pharma Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults Sabine Mueller, MD, PhD NA
RECRUITING
(Apr 1, 2026)
PHASE2 Reinforcing Effects of Marijuana and Opioids Shanna Babalonis, PhD NA
COMPLETED
(Apr 1, 2026)
PHASE1 HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML Sunshine Lake Pharma Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE3 An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Ionis Pharmaceuticals, Inc. NA
ENROLLING BY INVITATION
(Apr 1, 2026)
PHASE3 Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Herniorrhaphy for Postoperative Pain Cali Pharmaceuticals LLC NA
COMPLETED
(Apr 1, 2026)
PHASE3 Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy Debiopharm International SA NA
TERMINATED
(Apr 1, 2026)
PHASE1 A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients JW Pharmaceutical NA
COMPLETED
(Apr 1, 2026)
PHASE3 Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma Lyell Immunopharma, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 CPL-01 in the Management of Postoperative Pain After Bunionectomy Cali Pharmaceuticals LLC NA
COMPLETED
(Apr 1, 2026)
PHASE3 Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older Vertex Pharmaceuticals Incorporated NA
ENROLLING BY INVITATION
(Apr 1, 2026)
PHASE3 A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales Meiji Seika Pharma Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE3 Study of LP-184 in Patients With Advanced Solid Tumors Lantern Pharma Inc. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Deciphera Pharmaceuticals, LLC NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 PK and PD Study of NPI-001 and Cysteamine Bitartrate Nacuity Pharmaceuticals, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma Novelwise Pharmaceutical Corporation NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis NS Pharma, Inc. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia Ascendis Pharma A/S NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin EpiEndo Pharmaceuticals NA
COMPLETED
(Apr 1, 2026)
PHASE1 AMX0035 and Progressive Supranuclear Palsy Amylyx Pharmaceuticals Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE2, PHASE3 Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal Sarfez Pharmaceuticals, Inc. NA
WITHDRAWN
(Apr 1, 2026)
PHASE2 Parasitic Ulcer Treatment Trial Jeremy Keenan, MD, MPH NA
RECRUITING
(Apr 1, 2026)
PHASE3 Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome Noorik Biopharmaceuticals AG NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque NewAmsterdam Pharma NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence Philogen S.p.A. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. Laboratorios Sophia S.A de C.V. NA
COMPLETED
(Apr 1, 2026)
PHASE1 A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation Tyligand Pharmaceuticals (Suzhou) Limited NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
WITHDRAWN
(Apr 1, 2026)
PHASE1, PHASE2 To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer SUNHO（China）BioPharmaceutical CO., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Corvus Pharmaceuticals, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE3 STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer Angela Y. Jia, MD PhD NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy Vertex Pharmaceuticals Incorporated NA
RECRUITING
(Apr 1, 2026)
PHASE2 Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. Ascendis Pharma A/S NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis Calluna Pharma AS NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Nebulized Ketamine for the Treatment of Major Depressive Disorder Theresa Jacob, PhD, MPH NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects Fujian Shengdi Pharmaceutical Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE1 ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC ORIC Pharmaceuticals NA
RECRUITING
(Apr 1, 2026)
PHASE1 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension Joseph C. Wu NA
RECRUITING
(Apr 1, 2026)
PHASE1 Multiprofen-CC to Reduce Pain in Hand Arthritis St. Joseph's Healthcare Hamilton NA
RECRUITING
(Apr 1, 2026)
PHASE3 Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage Insud Pharma NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF Sunshine Lake Pharma Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE3 Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza Nanjing Zenshine Pharmaceuticals NA
COMPLETED
(Apr 1, 2026)
PHASE3 Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma Suzhou Zelgen Biopharmaceuticals Co.,Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE2 Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors CSPC ZhongQi Pharmaceutical Technology Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 BDB-001 Phase III Trial in ANCA-Associated Vasculitis Staidson (Beijing) Biopharmaceuticals Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer Shanghai Shengdi Pharmaceutical Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE3 Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma Intergroupe Francophone de Cancerologie Thoracique NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions Shanghai Shengdi Pharmaceutical Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Trial to Assess How Centanafadine Interacts With Stimulants in the Body Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1 Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia Beijing Continent Pharmaceutical Co, Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis TJ Biopharma Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) Verrica Pharmaceuticals Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE3 QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma Qilu Pharmaceutical Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. NA
RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) Dizal Pharmaceuticals NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors Zhejiang Anglikang Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Bioequivalence Study of Pramipexole Dihydrochloride Extended-release Tablets in Healthy Chinese Subjects Haisco Pharmaceutical Group Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE1 Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer Shanghai Shengdi Pharmaceutical Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL Philippe ROUSSELOT NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma CSPC Megalith Biopharmaceutical Co.,Ltd. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 ) Caliway Biopharmaceuticals Co., Ltd. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb) Beijing Tide Pharmaceutical Co., Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE2 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs Children's Hospital of Philadelphia NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis. Sun Pharmaceutical Industries, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1 A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia Jiangsu Hansoh Pharmaceutical Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE2 Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants Beijing QL Biopharmaceutical Co.,Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE1 Bioequivalence Study of Lidocaine and Prilocaine Cream in Healthy Chinese Subjects Haisco Pharmaceutical Group Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE1 SLN12140 in Adult Participants With IgA Nephropathy in China Linno Pharmaceuticals, Inc. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer R-Pharm International, LLC NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease Jiangsu Hansoh Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer. Nanjing Sanhome Pharmaceutical, Co., Ltd. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Bioequivalence Study of Tenofovir Disoproxil Fumarate Tablets in Healthy Chinese Subjects Haisco Pharmaceutical Group Co., Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE1 QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms Qilu Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy Jiangxi Qingfeng Pharmaceutical Co. Ltd. NA
COMPLETED
(Apr 1, 2026)
PHASE3 A 2-part Phase 1/2 Open-label Trial on ODM-212 Orion Corporation, Orion Pharma NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Drug-Drug Interaction Study of Atumelnant in Healthy Participants Crinetics Pharmaceuticals Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma International Extranodal Lymphoma Study Group (IELSG) NA
COMPLETED
(Mar 1, 2026)
PHASE2 Sublingual Cannabidiol for Anxiety Staci Gruber, Ph.D. NA
COMPLETED
(Mar 1, 2026)
PHASE2 A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Astellas Pharma Global Development, Inc. NA
TERMINATED
(Mar 1, 2026)
PHASE1, PHASE2 Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma The Lymphoma Academic Research Organisation NA
COMPLETED
(Mar 1, 2026)
PHASE2 A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML MEI Pharma, Inc. NA
TERMINATED
(Mar 1, 2026)
PHASE1 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers Novartis Pharmaceuticals NA
COMPLETED
(Mar 1, 2026)
PHASE1 PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product Staci Gruber, Ph.D. NA
RECRUITING
(Mar 1, 2026)
PHASE2 Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. Iperboreal Pharma Srl NA
RECRUITING
(Mar 1, 2026)
PHASE3 An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab Novartis Pharmaceuticals NA
COMPLETED
(Mar 1, 2026)
PHASE3 A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia BioMarin Pharmaceutical NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Apellis Pharmaceuticals, Inc. NA
COMPLETED
(Mar 1, 2026)
PHASE2 To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria Novartis Pharmaceuticals NA
COMPLETED
(Mar 1, 2026)
PHASE2 A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours PharmaMatrix Holdings Ltd NA
RECRUITING
(Mar 1, 2026)
PHASE1 Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Ono Pharmaceutical Co. Ltd NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome Stephen G. Kaler, MD NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) Sumitomo Pharma America, Inc. NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Study of Vimseltinib for Tenosynovial Giant Cell Tumor Deciphera Pharmaceuticals, LLC NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis COUR Pharmaceutical Development Company, Inc. NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) Ultragenyx Pharmaceutical Inc NA
COMPLETED
(Mar 1, 2026)
PHASE3 Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury Randy Trumbower, PT, PhD NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Vertex Pharmaceuticals Incorporated NA
RECRUITING
(Mar 1, 2026)
PHASE3 An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). Eupraxia Pharmaceuticals Inc. NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) Intergroupe Francophone de Cancerologie Thoracique NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors HighField Biopharmaceuticals Corporation NA
RECRUITING
(Mar 1, 2026)
PHASE1 Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage Simcere Pharmaceutical Co., Ltd NA
TERMINATED
(Mar 1, 2026)
PHASE2 Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma The Lymphoma Academic Research Organisation NA
RECRUITING
(Mar 1, 2026)
PHASE3 CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Marcela V. Maus, M.D.,Ph.D. NA
RECRUITING
(Mar 1, 2026)
PHASE1 A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease UCB Biopharma SRL NA
COMPLETED
(Mar 1, 2026)
PHASE2 A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause Astellas Pharma Inc NA
COMPLETED
(Mar 1, 2026)
PHASE3 Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder Sarfez Pharmaceuticals, Inc. NA
COMPLETED
(Mar 1, 2026)
PHASE2 PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers JW Pharmaceutical NA
COMPLETED
(Mar 1, 2026)
PHASE1 Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Gottfried von Keudell, MD PhD NA
RECRUITING
(Mar 1, 2026)
PHASE2 A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects Fujian Shengdi Pharmaceutical Co., Ltd. NA
COMPLETED
(Mar 1, 2026)
PHASE1 CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) COUR Pharmaceutical Development Company, Inc. NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin Basilea Pharmaceutica NA
COMPLETED
(Mar 1, 2026)
PHASE1 A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause Astellas Pharma Global Development, Inc. NA
COMPLETED
(Mar 1, 2026)
PHASE2 A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. Novartis Pharmaceuticals NA
COMPLETED
(Mar 1, 2026)
PHASE1 A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects Sarfez Pharmaceuticals, Inc. NA
COMPLETED
(Mar 1, 2026)
PHASE3 DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) Dizal Pharmaceuticals NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) Cascade Pharmaceuticals, Inc NA
RECRUITING
(Mar 1, 2026)
PHASE2 A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. PMV Pharmaceuticals, Inc NA
RECRUITING
(Mar 1, 2026)
PHASE1 A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet Guangzhou Lupeng Pharmaceutical Company LTD. NA
RECRUITING
(Mar 1, 2026)
PHASE1 A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients Novartis Pharmaceuticals NA
RECRUITING
(Mar 1, 2026)
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects Addpharma Inc. NA
RECRUITING
(Mar 1, 2026)
PHASE1 Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir Riphah International University NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE4 Comparing Two Root Canal Cleaning Solutions (Chlorhexidine vs. Sodium Hypochlorite) for Pain After Treatment College of Physicians and Surgeons Pakistan NA
NOT YET RECRUITING
(Mar 1, 2026)
QLS5132 Combination Therapy in Advanced Solid Tumors Qilu Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 TAR-0520 Gel in Hand and Foot Syndrome Tarian Pharma NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris Sun Pharmaceutical Industries, Inc. NA
COMPLETED
(Mar 1, 2026)
PHASE1 Counterpain PXM Versus Diclofenac Versus Piroxicam Taisho Pharmaceutical Indonesia NA
COMPLETED
(Mar 1, 2026)
PHASE3 A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity Chongqing Claruvis Pharmaceutical Co., Ltd. NA
RECRUITING
(Mar 1, 2026)
PHASE3 KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer Beijing Konruns Pharmaceutical Co., Ltd. NA
RECRUITING
(Mar 1, 2026)
PHASE2 Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients Chengdu Syncor Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets Shenzhen Salubris Pharmaceuticals Co., Ltd. NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1 A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol Sen-Jam Pharmaceutical NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP Ou Bai, MD/PHD NA
RECRUITING
(Mar 1, 2026)
PHASE3 Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL Ou Bai, MD/PHD NA
RECRUITING
(Mar 1, 2026)
PHASE2 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis Haisco Pharmaceutical Group Co., Ltd. NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE3 Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection Zhejiang Kanova Biopharmaceutical Co., LTD NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Oct, 2024)
PHASE2 Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep, 2024)
PHASE4 A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia NephroNet, Inc.
AstraZeneca
COMPLETED
(Jun, 2024)
PHASE4 Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients Novartis Pharmaceuticals NA
COMPLETED
(Jul, 2023)
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients Novartis Pharmaceuticals NA
COMPLETED
(Mar, 2023)
PHASE4 Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction Novartis Pharmaceuticals NA
COMPLETED
(Mar, 2020)
PHASE4 A Study of Oryz-Aspergillus Enzyme and Pancreatin Tablet in Patients With Cirrhosis and Malnutrition Shenzhen Kangzhe Pharmaceutical Co., Ltd. NA
UNKNOWN
(Aug, 2019)
NA Investigation of Flare and Remission in Subjects With Atopic Dermatitis LEO Pharma NA
WITHDRAWN
(Jul, 2019)
PHASE4 Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia Otsuka Pharmaceutical Europe Ltd
H. Lundbeck A/S
UNKNOWN
(Apr, 2019)
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction Novartis Pharmaceuticals NA
COMPLETED
(Feb, 2019)
PHASE3 Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia. ZS Pharma, Inc. NA
COMPLETED
(Jul, 2018)
PHASE3 Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. Otsuka Pharmaceutical Development & Commercialization, Inc. NA
TERMINATED
(Jan, 2016)
PHASE3 Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension Novartis Pharmaceuticals NA
COMPLETED
(Oct, 2015)
PHASE2 An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bayer
COMPLETED
(Aug, 2014)
PHASE3 Aripiprazole for the Augmentation of Antidepressant Therapy Taiwan Otsuka Pharm. Co., Ltd NA
COMPLETED
(May, 2014)
PHASE4 Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical
COMPLETED
(Feb, 2013)
PHASE3 Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients APT Pharmaceuticals, Inc. NA
NO LONGER AVAILABLE
(Sep, 2012)
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection Novartis Pharmaceuticals NA
COMPLETED
(Jul, 2012)
PHASE3 An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. NA
COMPLETED
(Apr, 2010)
PHASE2 Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF) Solvay Pharmaceuticals NA
COMPLETED
(Feb, 2010)
PHASE3 Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical
COMPLETED
(Aug, 2008)
PHASE4 Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders Otsuka Pharmaceutical Development & Commercialization, Inc. NA
COMPLETED
(Sep, 2007)
PHASE2, PHASE3 
